San Diego, CA ; 3/3/20
Amount Funded: $7 Million
Investor(s): CAM Capital, Charlie McDermott, BioBrit, BioRock Ventures
Company Description: Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.
What funding will be used for
To support development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate immunity.
“The recent advances in cancer immunotherapy have resulted in medicines that have had profound benefit for cancer patients; yet, a majority of those patients do not respond or relapse. There is a strong rationale for combining agents that activate systemic innate immunity, like a TLR7 agonist, with drugs that engage systemic adaptive immunity, like checkpoint inhibitors, to potentially address patients who have an inadequate response to approved treatments. We are pleased to have secured financial support from our investors and local biotech executives who are committed to supporting the advancement of our small molecule TLR7 agonists into human studies in oncology and virology.””
-Charlie McDermott, CEO, Primmune Therapeutics
- Scott Morenstien will be joining Primmune Therapeutics board of directors.
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.